Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 113-120

  Opstad, Trine B ^a,b   Pettersen, Alf Aage R ^a,b   Weiss, Thomas W ^a,b   Åkra, Sissel ^a,b   Øvstebø, Reidun ^a   Arnesen, Harald ^a,b,c   Seljeflot, Ingebjørg ^a,b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Coronary artery disease; Matrix metalloproteinase 9; MRNA; Single nucleotide polymorphism; Zymography

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; NITRATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; FEMALE; GENETIC VARIATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 82955249136     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.004     Document Type: Article

References (25)

1. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
2. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
3. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368-372.
4. Tayebjee M.H., Lip G.Y., Tan K.T., Patel J.V., Hughes E.A., MacFadyen R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005, 96:339-345.
5. Derosa G., D'Angelo A., Ciccarelli L., et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006, 13:227-231.
6. Yasmin, McEniery C.M., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005, 25:372.
7. Weiss T.W., Furenes E.B., Troseid M., et al. Prediction of cardiovascular events by matrix metalloproteinase (MMP)-9 in elderly men. Thromb Haemost 2010, 103:679-681.
8. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
9. Zhang B., Henney A., Eriksson P., Hamsten A., Watkins H., Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 1999, 105:418-423.
10. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
11. Abilleira S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006, 43:897-901.
12. Pettersen A.A., Seljeflot I., Abdelnoor M., Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38:353-356.
13. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
14. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994, 218:325-329.
15. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 2003, 81:321-326.
16. Haberbosch W., Gardemann A. Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest 2005, 65:513-522.
17. Cho H.J., Chae I.H., Park K.W., et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet 2002, 47:88-91.
18. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004, 24:1479-1484.
19. Maqbool A., Turner N.A., Galloway S., Riches K., O'Regan D.J., Porter K.E. The -1562C/T MMP-9 promoter polymorphism does not predict MMP-9 expression levels or invasive capacity in saphenous vein smooth muscle cells cultured from different patients. Atherosclerosis 2009, 207:458-465.
20. Wu S., Hsu L.A., Teng M.S., et al. Association of matrix metalloproteinase 9 genotypes and cardiovascular disease risk factors with serum matrix metalloproteinase 9 concentrations in Taiwanese individuals. Clin Chem Lab Med 2010, 48:543-549.
21. Gai X., Lan X., Luo Z., et al. Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients. Clin Chim Acta 2009, 408:105-109.
22. Wang Y.Y., Myhre A.E., Pettersen S.J., et al. Peptidoglycan of Staphylococcus aureus induces enhanced levels of matrix metalloproteinase-9 in human blood originating from neutrophils. Shock 2005, 24:214-218.
23. Yasmin, McEniery C.M., O'Shaughnessy K.M., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006, 26:1799-1805.
24. Lee S.W., Song K.E., Shin D.S., et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005, 69:175-179.
25. Furenes E.B., Seljeflot I., Solheim S., Hjerkinn E.M., Arnesen H. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand J Clin Lab Invest 2008, 68:177-184.